What is STAA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.13B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for STAA?

P/E (TTM) is 293.63 and 52-week range is $15.59 to $35.87 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s STAA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for STAA?

The company profile lists revenue (TTM) near $331M, net income (TTM) near $4M, EPS (TTM) near $0.07 when available from the market-data feed. Figures are informational and may lag live markets.

Where is STAAR Surgical Co based, and what identifiers does Chartloom list?

The company context section lists headquarters in Monrovia California, California, US, 50.1M shares outstanding, ISIN US8523123052 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

STAAR Surgical Co

$STAA

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.

Employees

957

Website

www.staar.com/

IPO

1992-02-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)